INTRODUCTION To examine the extent to which positron emission tomography (PET)‐,
cerebrospinal fluid (CSF)‐, and plasma‐related amyloid‐β/tau/neurodegeneration (A/T/N) …

Introduction This study aimed to assess whether biomarkers related to amyloid, tau, and
neurodegeneration can accurately predict Alzheimer's disease (AD) neuropathology at …

Alzheimer's disease biomarkers are widely accepted as surrogate markers of underlying
neuropathological changes. However, few studies have evaluated whether preclinical …

Background We aimed to investigate the tau biomarker discrepancies of Alzheimer's
disease (AD) using plasma tau phosphorylated at threonine 181 (p-tau181), cerebrospinal …

Background Recent advances in understanding the links between amyloid‐beta (Aβ) and
specific tau isoforms in brain, cerebrospinal fluid (CSF), and blood indicate that a cascade of …

Introduction Measurement of amyloid beta (Aβ40 and Aβ42) and tau (phosphorylated tau [p‐
tau] and total tau [t‐tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical …

Introduction Neuroimaging biomarkers are important for early diagnosis of Alzheimer's
disease, and comparing multimodality neuroimaging to autopsy data is essential. Methods …

Background Cerebrospinal fluid (CSF) p‐tau181 (tau phosphorylated at threonine 181) is an
established biomarker of Alzheimer's disease (AD) reflecting abnormal tau metabolism in …

INTRODUCTION Plasma biomarkers are promising tools for Alzheimer's disease (AD)
diagnosis, but comparisons with more established biomarkers are needed. METHODS We …

Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based
biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p …